Skip to Content
Merck
  • Dysferlin deficiency alters lipid metabolism and remodels the skeletal muscle lipidome in mice.

Dysferlin deficiency alters lipid metabolism and remodels the skeletal muscle lipidome in mice.

Journal of lipid research (2019-06-17)
Vanessa R Haynes, Stacey N Keenan, Jackie Bayliss, Erin M Lloyd, Peter J Meikle, Miranda D Grounds, Matthew J Watt
ABSTRACT

Defects in the gene coding for dysferlin, a membrane-associated protein, affect many tissues, including skeletal muscles, with a resultant myopathy called dysferlinopathy. Dysferlinopathy manifests postgrowth with a progressive loss of skeletal muscle function, early intramyocellular lipid accumulation, and a striking later replacement of selective muscles by adipocytes. To better understand the changes underpinning this disease, we assessed whole-body energy homeostasis, skeletal muscle fatty acid metabolism, lipolysis in adipose tissue, and the skeletal muscle lipidome using young adult dysferlin-deficient male BLAJ mice and age-matched C57Bl/6J WT mice. BLAJ mice had increased lean mass and reduced fat mass associated with increased physical activity and increased adipose tissue lipolysis. Skeletal muscle fatty acid metabolism was remodeled in BLAJ mice, characterized by a partitioning of fatty acids toward storage rather than oxidation. Lipidomic analysis identified marked changes in almost all lipid classes examined in the skeletal muscle of BLAJ mice, including sphingolipids, phospholipids, cholesterol, and most glycerolipids but, surprisingly, not triacylglycerol. These observations indicate that an early manifestation of dysferlin deficiency is the reprogramming of skeletal muscle and adipose tissue lipid metabolism, which is likely to contribute to the progressive adverse histopathology in dysferlinopathies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-phospho-Insulin Receptor Substrate-1 (pTyr612) antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution